Abstract:Abstract Personalized oncology must overcome the complex challenge of distinct cancer phenotypes in each patient, formed in part in response to unique metabolic crosstalk among cells in the tumor microenvironment which can be a determining factor in therapeutic response. Although isotope tracing sheds light on differences of metabolite enrichments in tumor and normal tissues, quantifying the metabolic fluxes in patients remains elusive. The conventional metabolic flux analysis tools are unable to estimate patient metabolic fluxes because we are limited to a single time point enrichment datapoint from each patient’s in-vivo measurement at isotopic non-steady state. We overcame this challenge by generating training data from the limited patient data and implementing a machine learning model to predict fluxes. To generate training data, we first simulated constrained random fluxes and enrichment patterns at different time points using patient circulating metabolites enrichment via an isotopic non-stationary metabolic flux analysis framework. Using this data, we trained a convolutional neural network to predict flux ratios. To validate our model, we compared predicted flux ratios to the experimental data from mouse models for two different treatments. Our recent findings from a glioblastoma (GBM) mouse model study using conventional metabolic flux analysis revealed higher de novo guanosine monophosphate (GMP) synthesis in GBM than normal cortex. These tumors can be sensitive to mycophenolate mofetil (MMF) which inhibits inosine monophosphate dehydrogenase, but only if the major source of GMP production is de novo synthesis and not salvage. Our machine learning model can discriminate between sources of GMP synthesis in patients, thus enabling prediction of potential responders. Furthermore, we previously showed that serine uptake is higher in GBM than normal cortex, and a serine- and glycine-restricted diet slows tumor growth in mice. While both circulating serine and microenvironment-derived serine could account for serine uptake in GBM, we hypothesized that the circulating serine dependence would better predict response to dietary serine depletion. Hence, we combined patient scRNA-seq and metabolomics data to feed our neural network framework to estimate microenvironmental and circulating serine uptake in six patients with brain cancer. Thus, we have shown that our model can identify patients who will benefit from MMF treatment or a serine- and glycine-restricted diet, enabling administration of highly effective personalized treatments for GBM patients. Citation Format: Baharan Meghdadi, Anjali Mittal, Andrew J. Scott, Sravya Palavalasa, Daniel R. Wahl, Deepak Nagrath. Machine learning-based method to analyze metabolic fluxes of patient tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1789.

Tmet-02. Cell-Intrinsic Metabolic Phenotypes Identified In Glioblastoma Patients Using Mass Spectrometry Imaging Of 13C-Labeled Glucose Metabolism

Tmet-23. Mass Spectrometry-Based Metabolic Profiling And Imaging Of Astrocyte And Glioblastoma Invasive Margin Cells

Localized Metabolomic Gradients in Patient-Derived Xenograft Models of Glioblastoma

Tmic-52. Decoding Metabolic Interactions In Glioblastoma Tumor Microenvironment Through Comprehensive Spatial Transcriptomic And Proteomic Analysis

TMIC-82. SPATIAL AND SINGLE-CELL PROTEOMIC LANDSCAPING OF THE HYPOXIC MICROENVIRONMENT IN GLIOBLASTOMA

Deuterium metabolic imaging differentiates glioblastoma metabolic subtypes and detects early response to chemoradiotherapy

Figure 1 from Deuterium Metabolic Imaging Differentiates Glioblastoma Metabolic Subtypes and Detects Early Response to Chemoradiotherapy

Tmet-27. Machine Learning-Based Identification Of Metabolic Fluxes In Patient Brain Tumors

Figure 4 from Deuterium Metabolic Imaging Differentiates Glioblastoma Metabolic Subtypes and Detects Early Response to Chemoradiotherapy

Deuterium Metabolic Imaging Phenotypes Mouse Glioblastoma Heterogeneity Through Glucose Turnover Kinetics

Metabolomic characterization of human glioblastomas and patient plasma: a pilot study

Using mass spectrometry imaging to map fluxes quantitatively in the tumor ecosystem

Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors

Figure 3 from Deuterium Metabolic Imaging Differentiates Glioblastoma Metabolic Subtypes and Detects Early Response to Chemoradiotherapy

Path-03. Spatial-Resolved Metabolomics Analysis In Histological And Molecular Glioblastomas Using A Mof/Mxene-Assisted Ldi-Msi Platform

Metabolic Insight into Glioma Heterogeneity: Mapping Whole Exome Sequencing to In Vivo Imaging with Stereotactic Localization and Deep Learning

Metabolic-imaging of human glioblastoma live tumors: A new precision-medicine approach to predict tumor treatment response early

Nimg-69. Interrogation Of Glioblastoma Fatty-Acid Synthesis And Metabolism With Deuterium Metabolic Imaging

Abstract B050: Metabolic rewiring in human brain cancer

Abstract 1789: Machine learning-based method to analyze metabolic fluxes of patient tumors